Safety Study of Stem Cells Treatment in Diabetic Foot Ulcers
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01686139|
Recruitment Status : Unknown
Verified January 2016 by Dr. Itzhak Siev-Ner, Sheba Medical Center.
Recruitment status was: Not yet recruiting
First Posted : September 17, 2012
Last Update Posted : January 27, 2016
Diabetes Mellitus (DM) can be regarded as one of the "epidemics" of the western world.
DM contributes to severe morbidity and mortality due to damage in the target organs (neuropathy, vasculopathy, nephropathy, retinopathy).
It affects the quality of life of the patients because of increased rate of blindness, IHD, stroke, end stage renal failure, hemodialysis and lower limb amputations (LLA).The Diabetic Foot (DF) is defined as destruction or infection of tissue/s in the foot of diabetic patients due to neurological damage and / or different levels of Peripheral Vascular Disease (PVD). Diabetic foot complications are the most common cause of lower extremity amputations in the industrialized world. The lifetime occurence of Diabetic Foot Ulcers (DFU) is 20% in diabetic patients.
Between 15% - 25% of the foot ulcers will lead to lower limb amputations.
It has been shown that Mesenchymal Stem Cells (MSCs) could be an effective therapy for many diseases including acute respiratory distress syndrome, spinal cord injury, liver injury and critical limb ischemia.
Stem cells can be obtained from either the patient (autologous) or non-related healthy donors (allogeneic).
The purpose of this study is to determine the safety and efficacy of cultured Bone Marrow Mesenchymal Stromal Cells (BM-MSCs) from allogeneic donors for treatment of chronic leg wounds of diabetic patients.
|Condition or disease||Intervention/treatment||Phase|
|Type I Diabetes Mellitus With Ulcer Type II Diabetes Mellitus With Ulcer||Biological: ABMD-MSC||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||12 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase 1 Study: Treatment of Patients With Diabetic Foot Complications With Allogeneic Bone Marrow Derived Mesenchymal Stromal Cells (ABMD-MSC)|
|Study Start Date :||March 2016|
|Estimated Primary Completion Date :||March 2017|
|Estimated Study Completion Date :||December 2017|
The patient will receive multiple injections in one session during the study. The injections will take place in the chronic wound bed and in the third distal part of the treated shin (in the form of a ring).
Maximal amount of ABMD-MSC cells injected: 10-20*10^6 cells (up to volume of 20mL, depending on the wound size & patient weight).
10-20 x 10^6 cells/20mL
- Frequency of Adverse Events [ Time Frame: 6 months after treatment ]Frequency and severity of Adverse Events.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01686139
|Contact: Itzhak Siev-Ner, MDemail@example.com|
|Orthopedic Rehabilitation out-patient clinic, Sheba Medical Center||Not yet recruiting|
|Ramat Gan, Israel|
|Contact: Itzhak Siev-Ner, MD 03-530-3701 firstname.lastname@example.org|
|Principal Investigator: Itzhak Siev-Ner, MD|
|Principal Investigator:||Itzhak Siev-Ner, MD||Sheba Medical Center|